On behalf of the National Institutes of Health (NIH) and the Trans-NIH Nanotechnology Task Force, we are pleased to accept the gracious suggestion to co-sponsor the first Joint U.S.-China Symposium on Nanobiotechnology and Nanomedicine, to be convened in Beijing in October, 2008. The goal of this symposium will be to develop and apply nanotechnology to prevent, detect, diagnose and treat disease, and to consider the effect of exposure to nanomaterials on workers, the general public and the environment. We trust that this initial dialogue will comprise an important first step in sharing information, scientific brainstorming, and the development of mutually productive collaborations and working relationships between Chinese and American scientists. This activity falls under the Science &Technology bilateral agreement between the US and China.
    The National Institutes of Health (NIH) constitutes one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS), United States of America (USA.) NIH is the primary Federal agency for conducting and supporting medical research, and as such, it provides leadership and financial support to researchers in every state in the U.S., and throughout the world.
    The NIH is composed of 27 Institutes and Centers (ICs) each of which focuses on a different biomedical research area. Recognizing that nanotechnology has the potential to radically change the ways in which we study and conceptualize basic biological mechanisms, in 2006, we established the Trans-NIH Nanotechnology Task Force (TF) in order to improve coordination of NIH nanotechnology-related activities across ICs, prioritize key steps to advance the NIH mission through an integrated program of basic and translational nanotechnology research and training, and build partnerships nationally and internationally, to ensure development of a robust scientific enterprise in nanomedicine and nanobiology. The NIH Director is committed to the development of new international relationships to mutually benefit fellow scientists and to advance the pace of scientific knowledge.
Sincerely yours,
>> 1 >> 2 >> 3